Table 2.
Virus | Virus assay | Cell culture | Oral drops |
Dry extract |
p |
---|---|---|---|---|---|
EC50 (μg/ml) | |||||
RNA-virus (enveloped) | |||||
Influenza A, Chile 1/83 (H1N1) virus (FluA) | PFU | MDCK | >120 | 124.8a | n.c. |
Porcine Influenza A/California/07/2009 (pFluA) | PFU | MDCK | n.t. | 43.4a | n.c. |
Parainfluenza type 3 virus (Para 3) | PFU | MDCK | >120 | >100 | n.c. |
Respiratory syncytial virus, strain long (RSV) | PFU ELISA |
HEp-2 | 20.7 34.0 |
10.4 21.0 |
<0.001 <0.001 |
RNA-virus (non-enveloped) | |||||
Rhinovirus B subtype 14 (HRV 14) | PFU | HeLa | 73.1 | 50.5 | >0.05 |
Coxsackievirus subtype A9 (CA9) | PFU | BGM | 86.6 | >100 | n.c. |
DNA-virus (non-enveloped) | |||||
Adenovirus C subtype 5 (Adeno 5) | CPE ELISA |
HEp-2 | 66.4 40.6 |
13.8 10.0 |
<0.001 <0.001 |
EC50, concentration that inhibits the viral acitivity by 50%; n.c., not calculated (Inhibition in the maximum concentration for at least one preparation lower than 50%); n.t., not tested; p, significance (dry extract vs. oral drops).
Relative to virus addition to cells different concentrations of Sinupret® were added 1 h after infection and left on throughout the incubation period. The antiviral activity was determined in plaque-reduction assays (PFU) for FluA, pFluA, Para 3, RSV, HRV 14 and CA9 or with the analyses of a cytopathogenic effect (CPE) for Adeno 5. In addition for RSV and Adeno 5 data were ascertained by ELISA. The relative inhibition by Sinupret® was standardised by the virus control representing 100% infectivity (0% inhibition). The table shows the concentration-dependent anti-viral effect of Sinupret® by using a therapeutic protocol calculated as a 50% effective concentration (EC50). All data are based on means of two (Adeno 5 CPE, RSV PFU, pFluA, repetition of FluA) or three (FLuA, Para 3, HRV 14, CA9, Adeno 5 ELISA and RSV ELISA) replicates derived from two independent experiments.
Additional test with higher concentrations of dry extract used.